Clinical Trials Logo

Brucellosis clinical trials

View clinical trials related to Brucellosis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06007326 Completed - Brucellosis Clinical Trials

A Multicentre, Retrospective Study of Clinical Characteristics and Long-term Outcomes of Patients With Brucellosis

Start date: April 27, 2022
Phase:
Study type: Observational

This is a multicenter, retrospective clinical study, in patients with brucellosis, to analyze the clinical characteristics, complications, and the impact of different treatment options on long-term prognosis of patients with brucellosis. All hospitalized patients diagnosed with brucellosis between 2016 and 2021 were included from the electronic medical record systems of eight centers, collecting demographics, hospitalization information, clinical information, laboratories, imaging studies, treatment regimens, and disease outcome and other information.

NCT ID: NCT05418686 Completed - Clinical trials for Colchicine Resistance

Study of Colchicine Resistance in Familial Mediterranean Fever

COLCHI-RESIST
Start date: December 9, 2022
Phase: N/A
Study type: Interventional

Five to 10% of familial mediterranean patients are considered colchicine-resistant (i.e. patients with a persistent inflammatory syndrome, despite taking the maximum tolerated dose of colchicine daily). The recommended treatment in this case is a subcutaneous anti-interleukin 1 biotherapy (anakinra or canakinumab). These treatments are expensive (1,000 to 12,000 euros/month). However, for a patient to be considered colchicine-resistant, compliance with the treatment must be verified. Furthermore specific activation of the pyrin inflammasome by Clostrioides difficile toxin and the overrepresentation of these bacteria in the stools of our patients led us to systematically search for them in our resistant patients. The demonstration of the involvement of C. difficile in the imbalance of the disease has not yet been published. The colchiresist study aim to better characterize colchicine-resistance by confirming good compliance to treatment with colchicine hair measurement and by looking for clostrioides infection or intestinal dysbiosis.

NCT ID: NCT05398536 Completed - FMF Clinical Trials

Kinesiophobia in Familial Mediterranean Fever

Start date: January 8, 2018
Phase:
Study type: Observational

Kinesiophobia is a common problem in patients with rheumatic disease and can cause physical inactivity, social isolation, disability, and poor quality of life. This study aimed to evaluate kinesiophobia and associated factors in patients with familial Mediterranean fever (FMF). All patients were evaluated in terms of sociodemographic characteristics and assessed using the Tampa Kinesiophobia Scale (TKS), International Physical Activity Questionnaire (IPAQ), Fatigue Severity Scale (FSS), and Hospital Anxiety and Depression Scale (HADS).

NCT ID: NCT05177120 Completed - Clinical trials for Central Sensitisation

Central Sensitization in Familial Mediterranean Fever (FMF)

FMF
Start date: June 1, 2021
Phase:
Study type: Observational

Familial Mediterranean Fever (FMF) is an autosomal recessive inherited disease with a course of autoinflammation, which is characterized by the episodes of fever and serositis. Central sensitization (CS) is defined as increased response to normal or sub-threshold stimuli of central nervous system and its close relationship with many rheumatological diseases has been demonstrated in several studies. However, there are no data on the frequency of CS in FMF patients.

NCT ID: NCT04911283 Completed - Spinal Degeneration Clinical Trials

Brucella Serology and History of Brucellosis in Patients With Modic Changes Type 1

Start date: May 1, 2019
Phase:
Study type: Observational

Objective: This study aims to examine Brucella serology and history of brucellosis in patients with lumbar Modic changes (MCs) type 1, considering results from cross-sectional and case-control comparisons. Design: In comparative cross-sectional design, MCs type 1 patients (study group) and MCs type 2 patients (comparator group) were examined in terms of Brucella serology by using agglutination with Coombs test. In addition, in comparative case-control design, both of the MCs groups and age/sex-matched healthy controls were investigated for their medical history regarding brucellosis.

NCT ID: NCT04729218 Completed - Clinical trials for Familial Mediterranean Fever

The Movement Imagery Ability in Patients With Familial Mediterranean Fever

Start date: January 1, 2018
Phase:
Study type: Observational

Motor imagery is the mental representation of movement without any doing body movement. A main function of imagery is to aid the self-regulation of thoughts, feelings, and behaviours. Studies have shown to be more effective for individuals displaying a higher level of imagery ability when using imagery to improve motor and motivational outcomes, including self-efficacy. The aim of this study is to measure the movement imagery ability in patients with Familial Mediterranean Fever and compare it with healthy individuals.

NCT ID: NCT04301752 Completed - Brucellosis Clinical Trials

Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis

Start date: February 1, 2019
Phase:
Study type: Observational

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries. Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

NCT ID: NCT03747315 Completed - Clinical trials for Familial Mediterranean Fever

A Diagnostic Test for Familial Mediterranean Fever

DEPIST-FMF
Start date: December 15, 2018
Phase:
Study type: Observational

Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease (prevalence: 1-5 / 10,000 inhabitants). It is due to mutations of the MEFV gene, encoding variants of the Pyrin inflammasome. Inflammasomes are protein complexes of innate immunity producing pro-inflammatory cytokines (interleukin-1β). In vitro, preliminary results demonstrated that activation of the Pyrin inflammasome (measured by interleukin-1β concentration) by kinase inhibitors is significantly increased in FMF patients compared to subjects with a similar clinical picture, and healthy controls. In addition, a measure of cell death yielded significant results in differentiating patients from controls. The investigators hypothesize that this fast and simple functional test can serve as a diagnostic tool for FMF.

NCT ID: NCT03563300 Completed - Clinical trials for Familial Mediterranean Fever (FMF)

Gluten-related Disorders in Familial Mediterranean Fever Patients

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

It is known that the gluten-containing grains can be responsible for human diseases related to gluten exposure. These forms of gluten intolerance represent a heterogeneous set of conditions, including celiac disease (CD), wheat allergy (WA) and not celiac gluten sensitivity (NCGS), that combined seems to affect about 5-10% of the general population. NCGS is the most recent gluten-related disease, characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects in whom either celiac disease or wheat allergy previously has been excluded. However, as it is not known what component of the cereals causes the symptoms in NCGS patients, the investigators prefer the label of "Not-celiac wheat sensitivity" (NCWS). Typically, the NCWS diagnosis is made by exclusion. Furthermore, similarly to CD, the investigators had demonstrated that NCWS may be associated with other autoimmune disease (i.e. Hashimoto's thyroiditis). Among these autoimmune conditions, in our daily out clinic work, the investigators have observed an association between self-reported NCWS and Familial Mediterranean Fever (FMF). Our preliminary observational data indicate that some FMF patients relate their symptoms (especially gastrointestinal) to gluten assumption, then excluding it from diet and using gluten-free products, with partial remission of gastrointestinal symptoms. Therefore, FMF and NCGS share some clinical features, such as abdominal pain, diarrhea, arthralgia and arthritis, and tend to be commonly associated with other inflammatory and autoimmune diseases. This study has 2 major aims: 1.To evaluate the real relationship between the wheat ingestion and the gastrointestinal manifestations presented by FMF patients, self-reporting a NCWS. 2. To identify possible immunologic markers that may explain the mechanism underling FMF abdominal attack and wheat ingestion.

NCT ID: NCT03446209 Completed - Clinical trials for Familial Mediterranean Fever

Tocilizumab for the Treatment of Familial Mediterranean Fever

Start date: April 23, 2018
Phase: Phase 2
Study type: Interventional

Adult patients with Familial Mediterranean Fever, who have active disease